• Explore /
  • Poster
  • / A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW).

A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW).

Abstract Poster

Authors

A. Sartor

A. Oliver Sartor

Tulane Cancer Center, New Orleans, LA

A. Oliver Sartor , David Laidley , Frederic Pouliot , Stephan Probst , Robert Sabbagh , Giuseppe Esposito , Fred Saad , Nancy Stambler , Evan Y. Yu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session: Advanced Prostate Cancer

Track

Prostate Cancer - Advanced

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03939689

Citation

J Clin Oncol 39, 2021 (suppl 6; abstr TPS187)

DOI

10.1200/JCO.2021.39.6_suppl.TPS187

Abstract #

TPS187

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Evan Y. Yu

First Author: Evan Y. Yu

First Author: Scott T. Tagawa

First Author: Scott T. Tagawa